Interleukin-6 Inhibition with Tocilizumab for Relapsing MOG-IgG Associated Disorder

被引：0
|
作者：
Elsbernd, Paul [1 ]
Hoffmann, William [2 ]
Wingerchuk, Dean [3 ]
Carter, Jonathan [3 ]
机构：
[1] Mayo Clin, Neurol, Tempe, AZ USA
[2] Brooke Army Med Ctr, Neurol, Tempe, AZ USA
[3] Mayo Clin, Tempe, AZ USA
来源：
NEUROLOGY | 2021年 / 96卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
11
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Interleukin-6 Inhibition with Tocilizumab for MOG-IgG Associated Disorder
    Elsbernd, P. M.
    Hoffman, W.
    Wingerchuk, D.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 81 - 81
  • [2] Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review
    Elsbernd, Paul M.
    Hoffman, William R.
    Carter, Jonathan L.
    Wingerchuk, Dean M.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 48
  • [3] Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder
    Chen, John J.
    Flanagan, Eoin P.
    Bhatti, M. Tariq
    Jitprapaikulsan, Jiraporn
    Dubey, Divyanshu
    Lopez Chiriboga, Alfonso S.
    Fryer, James P.
    Weinshenker, Brian G.
    McKeon, Andrew
    Tillema, Jan-Mendelt
    Lennon, Vanda A.
    Lucchinetti, Claudia F.
    Kunchok, Amy
    McClelland, Collin M.
    Lee, Michael S.
    Bennett, Jeffrey L.
    Pelak, Victoria S.
    Van Stavern, Gregory
    Adesina, Ore-Ofe O.
    Eggenberger, Eric R.
    Acierno, Marie D.
    Wingerchuk, Dean M.
    Lam, Byron L.
    Moss, Heather
    Beres, Shannon
    Gilbert, Aubrey L.
    Shah, Veeral
    Armstrong, Grayson
    Heidary, Gena
    Cestari, Dean M.
    Stiebel-Kalish, Hadas
    Pittock, Sean J.
    NEUROLOGY, 2020, 95 (02) : E111 - E120
  • [4] MOG-IgG Associated Disease (MOG-AD) in Adults
    Petra Brayo
    Suma Shah
    Current Treatment Options in Neurology, 2021, 23
  • [5] MOG-IgG Associated Disease (MOG-AD) in Adults
    Brayo, Petra
    Shah, Suma
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2021, 23 (06)
  • [6] Longitudinal assessment of cognitive function in patients with non-relapsing MOG-IgG associated disease
    Risi, Mario
    Altieri, Manuela
    Bisecco, Alvino
    Rippa, Valentina
    Borgo, Riccardo Maria
    Maggi, Gianpaolo
    Cirillo, Mario
    d'Ambrosio, Alessandro
    Gallo, Antonio
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2025, 470
  • [7] Interleukin-6 as Potential Prognostic Biomarker in Relapsing MOG Antibody Disease
    McDonald, J.
    Sattarnezhad, N.
    Tomczak, A.
    Sumera, J.
    Lock, C.
    Han, M. H.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 35 - 36
  • [8] Efficacy and safety of tocilizumab treatment in refractory MOG-IgG related optic neuritis
    Xu, Xintong
    Wang, Yuhang
    Sun, Mingming
    Li, Yuyu
    Chen, Biyue
    Chen, Xiyun
    Xu, Quangang
    Wei, Shihui
    Zhou, Huanfen
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2024, 17
  • [9] MOG-IgG associated optic neuritis is not multiple sclerosis
    da Costa, Bruna Klein
    dos Passos, Giordani Rodrigues
    Becker, Jefferson
    Sato, Douglas Kazutoshi
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2017, 75 (10) : 687 - 691
  • [10] Recent developments in MOG-IgG associated neurological disorders
    Hegen, Harald
    Reindl, Markus
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2020, 13
12345